Clopidogrel Test

To aid in assessing Clopidogrel efficacy?

Clopidogrel is a widely used antiplatelet agent for the primary and secondary prevention of arterial thrombosis. Clopidogrel is administered as a pro-drug and is metabolized to its active metabolite by the hepatic cytochrome P450 2C19 (CYP2C19) enzyme. The active metabolite is responsible for the antiplatelet activity of Clopidogrel.

Recent studies demonstrate that DNA variations in the gene for CYP2C19 result in significantly reduced production of the active metabolite of clopidogrel. Additional studies demonstrate that patients with variants in the CYP2C19 gene, including CYP2C19*2 & 3, have reduced production of the active
metabolite of clopidogrel, reduced inhibition of platelet aggregation and increased incidence of coronary, cerebrovascular and coronary stent
thrombosis.2,3,4

 Learn More about Clopidogrel testing

Advantages of Genotyping in predicting response to CLOPIDOGREL TREATMENT

  • By establishing the CYP2C19 genotype the clinician can now accurately predict if clopidogrel treatment is likely to be effective in the patient requiring anti-platelet therapy.
  • In patients currently receiving clopidogrel treatment and in whom a concern exists regarding the potential anti-thrombotic efficacy of this agent determination of CYP2C19 genotype will assist in determining the likely antithrombotic benefit of established clopidogrel treatment.

 

 

What should I do now?

Discuss DNAdose with your doctor to see whether this test is right for you. Download a referral form here

All pharmacogenetic test results are interpreted and reported by clinical geneticists at GenesFX Health.

The GenesFX Health scientific advisory board comprises clinicians, geneticists, pharmacists and clinical pharmacologists.

 


References

1. Hulot JS, Bura A, Villard E et al Blood. 2006;108:2244-7
2. Collet JP, Hulot JS, Pena A et al. Lancet. 2009;373:309-17
3. Mega JL, Close SL, Wiviott SD et al. N Eng J Med. 2009;360
4. Tabassome S, Verstuft C, Mary- Krause M et al. N Eng J Med.2009;360

If you have any questions or require further information, please contact us